HRP20200368T1 - Hibridni imunoglobulin koji sadrži nepeptidilnu vezu - Google Patents

Hibridni imunoglobulin koji sadrži nepeptidilnu vezu Download PDF

Info

Publication number
HRP20200368T1
HRP20200368T1 HRP20200368TT HRP20200368T HRP20200368T1 HR P20200368 T1 HRP20200368 T1 HR P20200368T1 HR P20200368T T HRP20200368T T HR P20200368TT HR P20200368 T HRP20200368 T HR P20200368T HR P20200368 T1 HRP20200368 T1 HR P20200368T1
Authority
HR
Croatia
Prior art keywords
amino acids
fab
sequence
antibody
image
Prior art date
Application number
HRP20200368TT
Other languages
English (en)
Inventor
Daniel J. Capon
Original Assignee
Biomolecular Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomolecular Holdings Llc filed Critical Biomolecular Holdings Llc
Publication of HRP20200368T1 publication Critical patent/HRP20200368T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (16)

1. Spoj naznačen time, da ima strukturu: A — B - - - - - Z gdje je A biološki aktivna struktura spoja; gdje je Z proteinska komponenta spoja, koja proteinska komponenta sadrži jedan ili više polipeptida, kod čega barem jedan od jednog ili više polipeptida obuhvaća aminokiseline u slijedu koje (i) koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) koje se vežu na Fc receptor; i (iii) imaju na svom N-terminusu cistein ili selenocistein; gdje je B kemijska struktura koja veže A i Z; u čemu crtkana linija između B i Z predstavlja peptidilnu vezu između N-terminalnog cisteina ili selenocisteina polipeptida od Z i aminokiselinskog ostatka ili organskog kiselinskog ostatka od B; i u čemu puna linija između A i B predstavlja nepeptidilnu vezu koja sadrži strukturu: [image] u čemu Xa jest kemijska struktura koja sadrži ciklooktan kondenziran na dihidropiridazin; u čemu Ra predstavlja organsku strukturu koja se veže na jedno od A ili B, a Rb predstavlja organsku strukturu koja se veže na drugo od A ili B.
2. Spoj prema patentnom zahtjevu 1, naznačen time, da je Ra vezan na ciklooktan, a Rb je vezan na dihidropiridazin.
3. Spoj prema patentnom zahtjevu 1 ili 2, naznačen time, da Xaima strukturu: [image] u čemu Rajest H, alkil ili aril; ili njihov tautomer.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 - 3, naznačen time, da puna linija između A i B predstavlja nepeptidilnu vezu koja obuhvaća strukturu: [image] u čemu Rc jest H, alkil ili aril; ili njihov tautomer.
5. Spoj prema bilo kojem od patentnih zahtjeva 1 - 4,naznačen time, da su Ra i Rb nezavisno jedan od drugoga, organska struktura koja sadrži ili se sastoji od lanca od 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 ili više jedinica, gdje je svaka jedinica nezavisno izabrana iz skupine koja se sastoji od [PEG(y)]z, polialkilenglikola, polioksialkiliranog poliola, polivinilalkohola, polivinilalkiletera, poli(mliječne kiseline), poli(mliječne-glikolne kiseline), polisaharida, razgrananog ostatka C1-C10 alkila, C3-C10cikloalkana, C2-C10 alkena, C5-C10 cikloalkena, amina, sumpora, kisika, sukcinimida, maleimida, glicerola, triazola, izoksazolidina, C2-C5acila, C2-C5 acilamino, C2-C5aciloksi, sukcinila, malonila, glutarila, ftalila, adipoila, aminokiseline, arilne skupine, heteroarilne skupine, karbamata, kemijske strukture koja sadrži ciklooktan kondenziran na dihidropiridazin, kemijske strukture koja sadrži ciklookten kondenziran na triazol, kemijske strukture koja sadrži ciklookten kondenziran na izoksazolidin, dibenzociklooktena, dibenzoazaciklooktena, [image] [image] i [image] i u čemu X1 jest CH ili N, X2 jest CH2ili karbonilna skupina, a R5 jest arilna ili alkilna skupina; kod čega [PEG(y)] z jest: [image] u čemu Y=1-100, a Z=1-10.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 - 5, naznačen time, da Ra ili Rb i) jest privješen na A preko veze ugljik-dušik ili veze ugljik–sumpor; ii) jest privješen na A preko veze ugljik-dušik; iii) jest privješen na A preko veze ugljik-dušik, u čemu veza ugljik-dušik jest amidna veza; iv) jest privješen na A preko biološki labilne veze; v) jest privješen na A preko amidne veze između C-terminus aminokiseline od A i amino skupine u B; vi) jest privješen na A preko amidne veze između C-terminus aminokiseline od A i amino skupine u B, u čemu terminus aminokiseline jest cistein; vii) jest privješen na A preko veze ugljik-sumpor; viii) jest privješen na A preko veze ugljik-sumpor stvorene između Ra ili Rbi slobodnog tiola; ix) sadrži razgranani ostatak; ili x) jest pričvršćen na više od jednog A preko razgrananog ostatka.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 - 6, naznačen time, da A i) sadrži strukturu spoja koji je lijek, odobren za liječenje pacijenta pogođenog bolešću; ii) sadrži strukturu organskog spoja koji ima molekulsku masu manju od 1000 daltona, DNA aptamer, RNA aptamer, oligonukleotid, ili protein koji je biološki aktivan; iii) sadrži primarni ili sekundarni amin; iv) jest vezan na B preko primarnog ili sekundarnog amina; v) jest aripiprazol ili oseltamivir; vi sadrži sekundarni amin; vii) jest respiratorni lijek, antiasmatik, analgetik, antidepresiv, antianginozni lijek, antiaritmik, antihipertenziv, antidijabetik, antihistaminik, antiinfektiv, antibiotik, antiinflamatorni agens, antiparkinsonik, antipsihotik, antipiretik, antiulkusni agens, lijek za poremećaj pozornosti s hiperaktivnošću (ADHD), stimulans središnjeg živčanog sustava, dekongestiv, ili psihostimulans; viii) jest alprenolol, acebutolol, amidefrin, amineptin, amosulalol, amoksapin, amfetaminil, atenolol, atomoksetin, balofloksacin, bametan, befunolol, benazepril, benfluoreks, benzoktamin, betahistin, betaksolol, bevantolol, bifemelan, bisoprolol, brinzolamid, bufeniod, butetamin, kamilofin, karazolol, kartikain, karvedilol, kefalin, ciprofloksacin, klozapin, clobenzorex, klorprenalin, ciklopentamin, delapril, demeksiptilin, denopamin, dezipramin, desloratadin, dicklofenak, dimetofrin, dioksadrol, dobutamin, dopeksamin, doripenem, dorzolamid, droprenilamin, duloksetin, eltoprazin, enalapril, enoksacin, epinefhrin, ertapenem, esaprazol, esmolol, etoksadrol, fasudil, fendilin, fenetilin, fenfluramin, fenoldopam, fenoterol, fenproporeks, flecamid, fluoksetin, formoterol, frovatriptan, gaboksadol, garenoksacin, gatifloksacin, grepafloksacin, heksoprenalin, imidapril, indalpin, indecainid, indeloksazin hidroklorid, izokssuprin, isproniclin, labetalol, landiolol, lapatinib, levofacetoperan, lizinopril, lomefloksacin, lotrafiban, maprotilin, mecamilamin, meflokine, mepindolol, meropenem, metapramin, metaproterenol, metoksifenamin, dekstrorotari metilfenidat, metifenidat, metipranolol, metoprolol, mitoksantron, mivazerol, moeksipril, moprolol, moksifloksacin, nebivolol, nifenalol, nipradilol, norfloksacin, nortriptilin, nilidrin, olanzapin, oksamnikin, oksprenolol, oksifedrin, paroksetin, perheksilin, fenmetrazin, fenilefrin, fenilpropilmetilamin, foledrin, picilorex, pimetilin, pindolol, pipemidična kiselina, piridokain, praktolol, pradofloksacin, pramipeksol, pramiverin, prenalterol, prenilamin, prilocaln, prokaterol, pronetalol, propafenon, propranolol, propilheksedrin, protokilol, protriptilin, pseudoefedrin, reboksetin, rasagilin, (r)-rasagilin, repinotan, reproterol, rimiterol, ritodrin, safinamid, salbutamol/albuterol, salmeterol, sarizotan, sertralin, silodosin, sotalol, soterenol, sparfloksacin, spirapril, sulfinalol, sinefrin, tamsulozin, tebaniclin, tianeptin, tirofiban, tretokuinol, trimetazidin, troksipid, vareniklin, vildagliptin, viloksazin, vikuidil ili ksamoterol; ix) sadrži protein koji je biološki aktivan; x) sadrži sekretorni protein; xi) sadrži izvanstaničnu domenu proteina xii) je biološki aktivan tako da ima ciljnovezujuću aktivnost; xiii) jest nezavisno preklapajući protein ili njegov dio; xiv) jest glikosilirani protein; xv) sadrži unutarlančane disulfidne veze; xvi) veže citokin; xvii) veže se na citokin, kada citokin jest TNFα; xviii) sadrži atrijski natriuretski peptid (ANP), kalcitonin, kortikotropin oslobađajući hormon (CRH), endotelin, eksenatid, želučani inhibicijski peptid (GIP), glukagonu sličan peptid-1 (GLP-1), glukagonu sličan peptid-2 (GLP-2), analog od GLP-1 ili GLP-2, glukagon vazoaktivni intestinalni peptid (GVIP), grelin, peptid YY ili sekretin, ili njegov dio; xix) sadrži barem jedan odsječak aminokiselina u slijedu u sekvenci HGEGTFTSDVSSYLEEQAAKEFIAWLVKGRG; xx) sadrži barem jedan odsječak aminokiselina u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u teškom lancu od Fab ili od Fab’ od antitijela; xxi) sadrži barem jedan odsječak aminokiselina u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u laganom lancu od Fab ili od Fab’ od antitijela; xxii) sadrži barem jedan Fab ili Fab’ od antitijela, ili dio od barem jednog Fab ili Fab’; xxiii) adrži Fab-1 ili Fab’1, ili njihov dio od antitijela; xxiv) sadrži Fab-2 ili Fab’2, ili njihov dio od antitijela; xxv) sadrži dvije ruke od Fab ili Fab’ od antitijela; xxvi) sadrži barem jedan odsječak aminokiselina u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u jednolančanom antitijelu; ili xxvii) sadrži barem jedan odsječak aminokiselina u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u TNFα receptoru.
8. Spoj prema bilo kojem od patentnih zahtjeva 1 - 7,naznačen time, da Ra ili Rb i) jest organska struktura koja sadrži [PEG(y)]z skupinu; ii) jest organska struktura koja sadrži polialkilenglikol, polioksialkilirani poliol, polivinilalkohol, polivinilalkileter, poli(mliječnu kiselinu), poli(mliječnu-glikolnu kiselinu) ili polisaharidnu skupinu; iii) jest organska struktura koja sadrži C1-C4 alkilnu skupinu; iv jest organska struktura koja sadrži sukcinimid; v) jest organska struktura koja sadrži amin; vi) jest organska struktura koja sadrži sukcinil, malonil, glutaril, ftalil ili adipoil; vii) jest organska struktura koja sadrži malonil; viii) jest organska struktura koja sadrži aminokiselinu; ix) jest organska struktura koja sadrži cistein; x) jest organska struktura koja sadrži lizin; xi) jest organska struktura koja se sastoji od lanca od tri jedinice, izabrane iz skupine koja se sastoji od [PEG(y)]z, polialkilenglikola, polioksialkiliranog poliola, polivinilalkohola, polivinilalkiletera, poli(mliječne kiseline), poli(mliječne-glikolne kiseline), polisaharida, razgrananog ostatka, C1-C10alkila, C3-C10 cikloalkana, C2-C10 alkena, C5-C10 cikloalkena, amina, sumpora, kisika, sukcinimida, maleimida, glicerola, triazola, izoksazolidina, C2-C5 acila, C2-C5 acilamino, C2-C5 aciloksi, sukcinila, malonila, glutarila, ftalila, adipoila, aminokiseline, arilne skupine, heteroarilne skupine, karbamata, kemijske strukture koja sadrži ciklooktan kondenziran na dihidropiridazin, kemijske strukture koja sadrži ciklookten kondenziran na triazol, kemijske strukture koja sadrži ciklookten kondenziran na izoksazolidin, dibenzociklooktena, dibenzoazaciklooktena, [image] [image] [image] i [image] xii) jest organska struktura koja se sastoji od lanca od četiri jedinice odabrane iz skupine koja se sastoji od [PEG(y)]z, polialkilenglikola, polioksialkiliranog poliola, polivinilalkohola, polivinilalkiletera, poli(mliječne kiseline), poli(mliječne-glikolne kiseline), polisaharida, razgrananog ostatka, C1-C10 alkila, C3-C10 cikloalkana, C2-C10 alkena, C5-C10 cikloalkena, amina, sumpora, kisika, sukcinimida, maleimida, glicerola, triazola, izoksazolidina, C2-C5 acila, C2-C5 acilamino, C2-C5 aciloksi, sukcinila, malonila, glutarila, ftalila, adipoila, aminokiseline, arilne skupine, heteroarilne skupine, karbamata, kemijske strukture koja sadrži ciklooktan kondenziran na dihidropiridazin, kemijske strukture koja sadrži ciklookten kondenziran na triazol, kemijske strukture koja sadrži ciklookten kondenziran na izoksazolidin, dibenzociklooktena, dibenzoazaciklooktena, [image] [image] i [image] xiii) jest organska struktura koja se sastoji od lanca od pet jedinica izabranih iz skupine koja se sastoji od [PEG(y)]z, polialkilenglikola, polioksialkiliranog poliola, polivinilalkohola, polivinilalkiletera, poli(mliječne kiseline), poli(mliječne-glikolne kiseline), polisaharida, razgrananog ostatka, C1- C10 alkila, C3- C10 cikloalkana, C2- C10 alkena, C5- C10 cikloalkena, amina, sumpora, kisika, sukcinimida, maleimida, glicerola, triazola, izoksazolidina, C2- C5 acila, C2- C5 acilamino, C2- C5 aciloksi, sukcinila, malonila, glutarila, ftalila, adipoila, aminokiseline, arilne skupine, heteroarilne skupine, karbamata, kemijske strukture koja sadrži ciklooktan kondenziran na dihidropiridazin, kemijske strukture koja sadrži ciklookten kondenziran na triazol, kemijske strukture koja sadrži ciklookten kondenziran na izoksazolidin, dibenzociklooktena, dibenzoazaciklooktena, [image] [image] i [image] xiv) sadrži [PEG(y)]z iz skupine vezane na lizin; xv) sadrži C1-C4 acilnu skupinu vezanu na sukcinimidnu skupinu; xvi) sadrži lizin vezan na C1-C4 acil; xvii) sadrži [PEG(y)]z skupine koja je vezana na glutaril; xviii) je organska struktura koja se sastoji od lanca od tri, četiri ili pet jedinica izabranih iz skupine koja se sastoji od [PEG(y)]z, C2-C5 acila, sukcinila, malonila, glutarila, aminokiseline, kemijske strukture koja sadrži ciklooktan kondenziran na dihidropiridazin, kemijske strukture koja sadrži ciklookten kondenziran na triazol, kemijske strukture koja sadrži ciklookten kondenziran na izoksazolidin, dibenzociklooktena, dibenzoazaciklooktena, [image] [image] i [image] u čemu X1 jest CH ili N, X2 je CH2 ili karbonilna skupina, a R5je arilna ili alkilna skupina; u čemu [PEG(y)]z jest: [image] u čemu y = 1-100, a z = 1-10; xix) je veza; xx) jest cistein: xxi) ima linearnu strukturu; ili xxii) ima razgnananu strukturu; xxiii) ima strukturu: [image] xxiv) jest: [image] u čemu n jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40 ili 1-50; xxv) jest: [image] u čemu n jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40 ili 1-50, x jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 019, 20, 1-30, 1-40, ili 1-50; a z jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40, ili 1-50; xxvi) jest: [image] u čemu x jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40 ili 1-50, a z jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40 ili 1-50; ili xxvii) jest: [image] u čemu n jest 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 1-30, 1-40 ili 1-50.
9. Spoj prema bilo kojem od patentnih zahtjeva 1 - 8,naznačen time, da Z sadrži jedan C, u čemu C jest prvi polipeptid, koji prvi polipeptid sadrži aminokiseline u slijedu koje (i) su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na njihovom N-terminusu sekvencu izabranu iz skupine koja se sastoji od cisteina, selenocisteina, CP, CPXCP (gdje X = P, R, ili S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP i CDTPPPCPRCP.
10. Spoj prema patentnom zahtjevu 9, naznačen time, da C i) sadrži aminokiseline u slijedu koje (i) su identične odsječku aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na svojem N-terminusu sekvencu koja sadrži cistein koji se prirodno pojavljuje, odabran iz skupine koja se sastoji od CP, CPXCP (gdje X = P, R,ili S), CDKTHTCPPCP, CVECPPCP, CCVECPPCP i CDTPPPCPRCP; ii) jest polipeptidna komponenta spoja, koja polipeptidna komponenta sadrži aminokiseline u slijedu koje (i) su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela; (ii) vežu se na Fc receptor; i (iii) imaju na svojem N-terminusu sekvencu koja sadrži cistein ili selenocistein koji se prirodno ne pojavljuje; (iii) sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc domene antitijela izabranih iz skupine koja se sastoji od IgG, IgM, IgA, IgD, i IgE; iv) sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu Fc6 domene antitijela; v) sadrži amino kiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu antitijela različitom od lanca Fc domene antitijela; vi) aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u teškom lancu od Fab ili Fab’ antitijela; ili vii) sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u laganom lancu od Fab ili Fab’ antitijela.
11. Spoj prema patentnom zahtjevu 9 ili 10, naznačen time, da Z nadalje sadrži drugi polipeptid, koji drugi polileptid sadrži aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u lancu antitijela različitom od lanca Fc domene antitijela.
12. Spoj prema patentnom zahtjevu 11, naznačen time, da drugi polipeptid sadrži i) aminokiseline u slijedu koje su identične s odsječkom amino kiselina u slijedu prisutnih u teškom lancu od Fab ili Fab’ antitijela; ili ii) aminokiseline u slijedu koje su identične s odsječkom aminokiselina u slijedu prisutnih u laganom lancu od Fab ili Fab’ antitijela.
13. Spoj prema bilo kojem od patentnih zahtjeva 1 - 12, naznačen time, da Z i) sadrži antitijelo ili njegov dio; ii) sadrži barem jedan Fab ili Fab’ antitijela, ili dio od barem jednog Fab ili Fab’; iii) sadrži Fab-1 ili Fab’1, ili njihov dio od antitijela; iv) sadrži Fab-2 ili Fab’2, ili njihov dio od antitijela; v) sadrži dvije ruke od Fab ili Fab’ antitijela; vi) sadrži barem jedan odsječak aminokiselina u slijedu, koje su identične s jednim odsječkom aminokiselina u slijedu prisutnih u jedinom lancu antitijela; ili vii) sadrži drugi polipeptid, a B je vezan na Z preko peptidilne veze između N-terminus cisteina ili selenocisteina drugog polipeptida od Z i aminokiselinskog ostatka ili organskog kiselinskog ostatka od B.
14. Spoj prema bilo kojem od patentnih zahtjeva 9 – 13, naznačen time, da C-terminus od C i) sadrži odsječak aminokiselina u slijedu prisutnih u lancu Fc domene od antitijela koje je modificirano; ili ii) jest cistein, selenocistein, homocistein, ili homoselenosistein, ili derivat cisteina, selenocisteina, homocisteina, ili homoselenosisteina.
15. Homodimer ili heterodimer, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1-14.
16. Homodimer ili heterodimer prema patentnom zahtjevu 15,naznačen time, da se svaki spoj homodimera ili heterodimera i) može vezati na drugi preko barem jedne disulfidne veze; ii) može vezati na drugi preko barem jedne disulfidne veze između C ili drugog polipeptida svakog spoja; iii) je vezan na drugi preko barem jedne disulfidne veze; iv) je vezan na drugi barem jednom disulfidnom vezom između C ili drugog polipeptida svakog spoja.
HRP20200368TT 2014-03-14 2020-03-04 Hibridni imunoglobulin koji sadrži nepeptidilnu vezu HRP20200368T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461953650P 2014-03-14 2014-03-14
EP15760986.8A EP3116486B1 (en) 2014-03-14 2015-03-13 Hybrid immunoglobulin containing non-peptidyl linkage
PCT/US2015/020458 WO2015138907A2 (en) 2014-03-14 2015-03-13 Hybrid immunoglobulin containing non-peptidyl linkage

Publications (1)

Publication Number Publication Date
HRP20200368T1 true HRP20200368T1 (hr) 2020-06-26

Family

ID=54072599

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20221233TT HRP20221233T1 (hr) 2014-03-14 2015-03-13 Spojevi korisni u pripravi hibridnog imunoglobina koji sadrži nepeptidilnu vezu
HRP20200368TT HRP20200368T1 (hr) 2014-03-14 2020-03-04 Hibridni imunoglobulin koji sadrži nepeptidilnu vezu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20221233TT HRP20221233T1 (hr) 2014-03-14 2015-03-13 Spojevi korisni u pripravi hibridnog imunoglobina koji sadrži nepeptidilnu vezu

Country Status (18)

Country Link
US (2) US11066459B2 (hr)
EP (3) EP4169944A1 (hr)
JP (3) JP6893598B2 (hr)
KR (2) KR102587838B1 (hr)
CN (1) CN106456574A (hr)
AU (2) AU2015229186B2 (hr)
CA (1) CA2942685C (hr)
DK (2) DK3701971T3 (hr)
ES (2) ES2932285T3 (hr)
HR (2) HRP20221233T1 (hr)
IL (3) IL247801B (hr)
LT (2) LT3116486T (hr)
MX (1) MX2016011934A (hr)
NZ (1) NZ724904A (hr)
PT (2) PT3116486T (hr)
SG (2) SG11201607579TA (hr)
SI (2) SI3701971T1 (hr)
WO (1) WO2015138907A2 (hr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6231263B2 (ja) 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
CA2906175C (en) 2013-03-15 2022-12-13 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
SG11201607579TA (en) * 2014-03-14 2016-10-28 Daniel J Capon Hybrid immunoglobulin containing non-peptidyl linkage
ES2607639B1 (es) 2015-09-30 2018-02-28 Urquima, S.A Sal de ácido maleico de un intermedio de silodosina
CN105527433A (zh) * 2015-12-18 2016-04-27 南京邮电大学 一种检测肿瘤标志物的荧光方法
CA3013829A1 (en) * 2016-02-09 2017-08-17 Alexander Krantz Site-selective functionalization of proteins using traceless affinity labels
WO2017191817A1 (ja) 2016-05-02 2017-11-09 味の素株式会社 アジド基含有Ｆｃタンパク質
US11925691B2 (en) 2017-02-07 2024-03-12 Hanmi Pharm. Co., Ltd. Non-peptidic polymeric linker compound, conjugate comprising same linker compound, and methods for preparing same linker compound and conjugate
ES2919779T3 (es) 2017-06-20 2022-07-28 Imbria Pharmaceuticals Inc Derivado de 1-[(2,3,4-trimetoxifenil)metil]-piperazina, composiciones del mismo y métodos para aumentar la eficiencia del metabolismo cardíaco
CA3081543A1 (en) * 2017-11-03 2019-05-09 Fluidigm Canada Inc. Reagents and methods for elemental imaging mass spectrometry of biological samples
JP2021502418A (ja) 2017-11-04 2021-01-28 アドバンスト・プロテオーム・セラピューティクス・インコーポレイテッド ポリペプチドを修飾するための組成物及び方法
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
WO2022011358A1 (en) * 2020-07-10 2022-01-13 Biomolecular Holdings Llc Tetrahedral antibodies
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
CN115671308A (zh) * 2021-07-30 2023-02-03 北京键凯科技股份有限公司 一种靶向性的抗体-聚乙二醇-siRNA药物偶联物
FR3139820A1 (fr) * 2022-09-15 2024-03-22 Universite Toulouse III – Paul Sabatier Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une vascularite auto-immune, et ses utilisations
FR3139821A1 (fr) * 2022-09-15 2024-03-22 Universite Toulouse III – Paul Sabatier Molécule hybride comprenant un fragment Fc d’anticorps et au moins un peptide se liant à un lymphocyte auto-réactif impliqué dans une dermatite auto-immune, et ses utilisations

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4943529A (en) 1982-05-19 1990-07-24 Gist-Brocades Nv Kluyveromyces as a host strain
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
AU3145184A (en) 1983-08-16 1985-02-21 Zymogenetics Inc. High expression of foreign genes in schizosaccharomyces pombe
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JPS63502716A (ja) 1986-03-07 1988-10-13 マサチューセッツ・インステチュート・オブ・テクノロジー 糖タンパク安定性の強化方法
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946783A (en) 1987-01-30 1990-08-07 President And Fellows Of Harvard College Periplasmic protease mutants of Escherichia coli
US5010182A (en) 1987-07-28 1991-04-23 Chiron Corporation DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides
IL87737A (en) 1987-09-11 1993-08-18 Genentech Inc Method for culturing polypeptide factor dependent vertebrate recombinant cells
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
GB8724885D0 (en) 1987-10-23 1987-11-25 Binns M M Fowlpox virus promotors
ATE105585T1 (de) 1987-12-21 1994-05-15 Univ Toledo Transformation von keimenden pflanzensamen mit hilfe von agrobacterium.
AU4005289A (en) 1988-08-25 1990-03-01 Smithkline Beecham Corporation Recombinant saccharomyces
DE394538T1 (de) 1989-04-28 1991-04-11 Rhein Biotech Ges. Fuer Biotechnologische Prozesse Und Produkte Mbh, 4000 Duesseldorf, De Hefezellen der schwanniomyces-gattung.
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
CA2074825C (en) 1990-12-14 2005-04-12 Daniel J. Capon Chimeric chains for receptor-associated signal transduction pathways
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
US5536637A (en) 1993-04-07 1996-07-16 Genetics Institute, Inc. Method of screening for cDNA encoding novel secreted mammalian proteins in yeast
US5838464A (en) 1995-11-02 1998-11-17 Eastman Kodak Company System and method for scanning images contained on a strip of photosensitive film
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US6165476A (en) 1997-07-10 2000-12-26 Beth Israel Deaconess Medical Center Fusion proteins with an immunoglobulin hinge region linker
US20030044839A1 (en) 1997-09-17 2003-03-06 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
AU2003217746A1 (en) 2002-02-28 2003-09-16 New England Biolabs, Inc. Modified chitin binding domain and uses thereof
US20090042291A1 (en) 2002-03-01 2009-02-12 Xencor, Inc. Optimized Fc variants
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI353991B (en) * 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
US7947261B2 (en) 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
ZA200509059B (en) 2003-05-30 2007-01-31 Genentech Inc Treatment with anti-VEGF antibodies
KR20120116991A (ko) 2003-07-29 2012-10-23 시그너쳐 알 앤드 디 홀딩스, 엘엘씨 아미노산 프로드럭
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
JP2008523073A (ja) 2004-12-07 2008-07-03 ジェネンテック・インコーポレーテッド Ｈｅｒ阻害剤を用いた治療のための患者の選択
US20070122408A1 (en) 2005-10-20 2007-05-31 The Scripps Research Institute Fc Labeling for Immunostaining and Immunotargeting
GB0614780D0 (en) * 2006-07-25 2006-09-06 Ucb Sa Biological products
WO2008140477A2 (en) 2006-11-02 2008-11-20 Capon Daniel J Hybrid immunoglobulins with moving parts
WO2008154226A1 (en) * 2007-06-06 2008-12-18 Boehringer Ingelheim International Gmbh Natriuretic fusion proteins
US20090181037A1 (en) * 2007-11-02 2009-07-16 George Heavner Semi-Synthetic GLP-1 Peptide-FC Fusion Constructs, Methods and Uses
RU2536937C2 (ru) 2008-10-14 2014-12-27 Дженентек, Инк. Варианты иммуноглобулина и их применения
WO2010051530A2 (en) * 2008-10-31 2010-05-06 The General Hospital Corporation Compositions and methods for delivering a substance to a biological target
CA2749501C (en) 2009-02-13 2017-01-10 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
WO2010117760A2 (en) * 2009-03-30 2010-10-14 Boehringer Ingelheim International Gmbh Fusion proteins comprising canine fc portions
ES2769538T3 (es) * 2009-04-16 2020-06-26 Tagworks Pharmaceuticals B V Kit de predireccionamiento, método y agentes que se usan en éste
WO2010129248A1 (en) * 2009-05-06 2010-11-11 Centocor Ortho Biotech Inc. Melanocortin receptor binding conjugates
US10434197B2 (en) 2010-07-23 2019-10-08 University Of Delaware Tetrazine-trans-cyclooctene ligation for the rapid construction of radionuclide labeled probes
JP2014509859A (ja) 2011-03-16 2014-04-24 アムジエン・インコーポレーテツド １７ｎａｖ１．３およびｎａｖ１．７の強力かつ選択的阻害剤
ES2744226T3 (es) 2011-05-08 2020-02-24 Legochem Biosciences Inc Conjugados de proteína-agente activo y método para preparar los mismos
CN103732257A (zh) * 2011-05-16 2014-04-16 皇家飞利浦有限公司 生物正交药物活化
EP2726494B1 (en) 2011-06-28 2017-01-04 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
CA2840221A1 (en) 2011-07-05 2013-01-10 Bioasis Technologies Inc. P97-antibody conjugates and methods of use
WO2013065343A1 (ja) * 2011-10-31 2013-05-10 株式会社 島津製作所 非ペプチドヒンジ部含有フレキシブル抗体様分子
TWI476001B (zh) * 2011-12-26 2015-03-11 Ind Tech Res Inst 三倍體Ｆｃ融合蛋白及其用途
JP6333802B2 (ja) 2012-03-19 2018-05-30 アルカームス ファーマ アイルランド リミテッド ベンジルアルコールを含む医薬組成物
CN104519897A (zh) * 2012-06-08 2015-04-15 比奥根艾迪克Ma公司 促凝血化合物
WO2014004639A1 (en) * 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
JP6231263B2 (ja) 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
CA2906175C (en) 2013-03-15 2022-12-13 Daniel J. Capon Hybrid immunoglobulin containing non-peptidyl linkage
SG11201607579TA (en) * 2014-03-14 2016-10-28 Daniel J Capon Hybrid immunoglobulin containing non-peptidyl linkage

Also Published As

Publication number Publication date
CN106456574A (zh) 2017-02-22
ES2932285T3 (es) 2023-01-17
WO2015138907A3 (en) 2016-01-21
ES2788973T3 (es) 2020-10-23
US20170008950A1 (en) 2017-01-12
EP3701971B1 (en) 2022-07-06
KR102475799B1 (ko) 2022-12-08
EP3116486A4 (en) 2017-11-08
LT3701971T (lt) 2023-01-10
PT3116486T (pt) 2020-03-12
IL270364B (en) 2022-02-01
EP4169944A1 (en) 2023-04-26
WO2015138907A2 (en) 2015-09-17
JP7475690B2 (ja) 2024-04-30
SI3116486T1 (sl) 2020-07-31
SI3701971T1 (sl) 2023-01-31
LT3116486T (lt) 2020-04-10
EP3701971A1 (en) 2020-09-02
HRP20221233T1 (hr) 2022-12-09
MX2016011934A (es) 2017-04-13
JP2021107391A (ja) 2021-07-29
CA2942685C (en) 2023-09-05
KR20230010667A (ko) 2023-01-19
EP3116486B1 (en) 2019-12-04
IL247801B (en) 2020-05-31
IL290135A (en) 2022-03-01
KR102587838B1 (ko) 2023-10-12
DK3116486T3 (da) 2020-03-09
PT3701971T (pt) 2022-10-03
DK3701971T3 (da) 2022-10-24
US20210340222A1 (en) 2021-11-04
KR20170004967A (ko) 2017-01-11
JP2024023196A (ja) 2024-02-21
NZ724904A (en) 2023-04-28
EP3116486A2 (en) 2017-01-18
AU2021202315A1 (en) 2021-05-13
AU2015229186A1 (en) 2016-10-27
US11066459B2 (en) 2021-07-20
SG11201607579TA (en) 2016-10-28
AU2015229186B2 (en) 2021-01-28
JP6893598B2 (ja) 2021-06-23
CA2942685A1 (en) 2015-09-17
JP2017516839A (ja) 2017-06-22
IL247801A0 (en) 2016-11-30
SG10201807877TA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
HRP20200368T1 (hr) Hibridni imunoglobulin koji sadrži nepeptidilnu vezu
JP2021107391A5 (hr)
RU2428431C2 (ru) Слитые конструкции лекарственного средства и конъюгаты
US20090092578A1 (en) Methods of selecting and producing modified toxins, conjugates containing modified toxins, and uses thereof
RU2011125367A (ru) Конъюгаты лептина и аналогов лептина и их применение
CY1110488T1 (el) Μεθοδος για την παρασκευη καρβοξυ-τερματικων αμιδουχων πεπτιδιων
JP2013505221A (ja) 長時間作用性ｙ２受容体アゴニスト
RU2007119989A (ru) Композиции, слитые конструкции и конъюгаты plad домена
RU2506270C2 (ru) Пептид-антагонист активности интерлейкина-15
US20210061856A1 (en) Cell-permeable stapled peptide modules for cellular delivery
JP2015517478A (ja) 二重アシル化されたｇｌｐ−１誘導体
JP2023535677A (ja) 四面体抗体
KR101898502B1 (ko) 인슐린-유사 성장 인자 1 수용체 결합 펩티드
TW200838558A (en) New immunomodulating oligopeptides
Kratzel et al. Auxiliary agents for the peroral administration of peptide and protein drugs: Synthesis and evaluation of novel pepstatin analogues
US20230220115A1 (en) Tetrahedral antibodies
JP6975437B2 (ja) 細胞層透過促進剤、薬剤吸収補助用組成物、及び医薬組成物
US20240158526A1 (en) Topologically engineered superdimeric antibodies
WO2023137387A2 (en) Tetrahedral antibodies